ARTICLE | Deals
Amid flurry of COVID-19 deals, Vir turns to Samsung to ramp up manufacturing
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
April 10, 2020 9:18 PM UTC
Updated on Apr 17, 2020 at 12:27 PM UTC
While its two SARS-CoV-2 antibodies are still months away from entering the clinic, Vir has wasted no time securing manufacturing capacity. The biotech Friday partnered with Samsung Biologics, marking its fourth manufacturing deal.
Vir Biotechnology Inc. (NASDAQ:VIR) expects to start a Phase II trial within three to five months of two versions of an antibody product, VIR-7831 and VIR-7832, which target the spike protein of SARS-CoV-2...